Cambridge, Massachusetts-based genome editing company Intellia Therapeutics said China’s State Intellectual Property Office (SIPO) indicated it will grant a patent broadly covering CRISPR/Cas9 single-guide gene editing methods and compositions.
“The patent includes claims covering methods for editing DNA in non-cellular and cellular settings, including in eukaryotic cells such as human and mammalian cells,” said Intellia.
“It also includes CRISPR/Cas9 composition of matter and system claims for use in any setting, including claims covering the use of CRISPR/Cas9 in producing medicines for treating disease.”
Intellia Therapeutics CEO Nessan Bermingham said: “SIPO’s decision further expands our IP portfolio, and is further global recognition that Jennifer Doudna, Emmanuelle Charpentier and their team are the pioneers in the application of CRISPR/Cas9 in all cell types.
“Intellia continues to build on preclinical work and to focus on the development of our pipeline of novel human therapeutics that will potentially transform the lives of patients with genetic diseases.”